Premium
Transforming growth factor‐β1 serum concentration
Author(s) -
; Wolff,
Fandel,
Borchers,
Brehmer Jr,
Jakse
Publication year - 1998
Publication title -
british journal of urology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.773
H-Index - 148
eISSN - 1464-410X
pISSN - 0007-1331
DOI - 10.1046/j.1464-410x.1998.00560.x
Subject(s) - medicine , prostate cancer , hyperplasia , prostate , stage (stratigraphy) , urology , transforming growth factor , prostate specific antigen , cancer , endocrinology , gastroenterology , biology , paleontology
Objective To assess serum levels of transforming growth factor‐β1 (TGF‐β1), normally markedly elevated in prostate cancer tissue, in patients with cancer of the prostate, and to correlate these levels with tumour stage and serum prostate specific antigen (PSA) levels. Patients and methods Serum TFG‐β1 and PSA levels were determined in 32 patients with untreated prostate cancer. Patients were divided into: group 1, 14 patients with pT1–3pN0M0; group 2, four with T1–3pN+M0; and group 3, 14 with T1–4NxM+. Ten patients with histologically confirmed benign prostatic hyperplasia (BPH) served as controls. Results The median TGF‐β1 levels were no different between patients with cancer or BPH (30.7 ng/mL and 26.9 ng/mL, respectively; P >0.05). Furthermore, there was no increase in TGF‐β1 concentrations with advancing tumour stage (group 1, 34.1 ng/mL; group 2, 33.0 ng/mL; group 3, 28.3 ng/mL; P >0.05). There was no correlation with PSA levels (group 1, r =−0.42; group 2, r =−0.43; group 3, r =−0.23; BPH, r =0.38). Conclusion TGF‐β1 levels did not discriminate between patients with BPH and prostate cancer, and there was no increase in TGF‐β1 levels with advancing tumour stage.